The invention relates to biomarkers in the umbilical cord epithelium relating to skin proteins that are better predictive for the development of atopic dermatitis late in life. These biomarkers enable an early nutritional intervention in a more precisely determined population of at risk infants.

The present disclosure provides a reagent kit for detecting a sex hormone, which contains a first reagent containing a metal nanoprobe in which a sex hormone and a Raman reporter are immobilized and a second reagent containing a magnetic particle in which an antibody for detecting the sex hormone is immobilized, and a method for detecting a sex hormone using the same.

The disclosure relates to methods of preparation of fetal nucleated red blood cells (NRBCs) from biological samples for diagnostic testing.

Provided is an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to sepsis and/or necrotizing enterocolitis in pediatric patients. In particular, the invention relates to identifying two or more biomarkers associated with septic shock in pediatric patients, obtaining a sample from a pediatric patient having at least one indication of sepsis and/or necrotizing enterocolitis, then quantifying from the sample an amount of two or more of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.

Provided are methods for diagnosing a disease in a subject with a previous streptococcal infection by determining the presence or absence of one or more autoantibodies in a biological sample from the subject, wherein the one or more autoantibodies recognize an antigen from a protein selected from the group consisting of ELAVL2, ELAVL3, ELAVL4, Nova-1, Nova-2, Cdr1, Cdr2; and Cdr3. The presence of such autoantibodies is indicative of a positive diagosis for a post-streptococcal disease such as PANDAS, post-GABHS glomerulonephritis, rheumatic fever, autism and Syndenham's chorea.

The present invention relates to a method for measuring growth hormone level in a human child, including a method of assessing pituitary-related growth hormone deficiency in a human child as a stand-alone test. The method comprises oral administration of an effective amount of macimorelin to the child, collecting from the child two or up to four post-administration blood samples within a range of about 90 minutes after administration, and determining the level of growth hormone in the samples. The method can be used for diagnosing pituitary-related growth hormone deficiency in a child when the peak level of determined growth hormone in the samples is below a cut-off value.

This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.

The invention relates to allergic disease, to the development of allergic disease in infants, to determining the likelihood of development of allergic disease in infants and to minimizing the likelihood of development of allergic disease in infants.

Compositions and methods are provided for diagnosis, prognosis, and/or monitoring of Kawasaki disease or MIS-C (e.g., associated with SARS-CoV-2 infection) in a subject. In some embodiments, the method includes measuring, comparing and weighting the level of particular proteins to other proteins. In other embodiments, the method includes comparison with clinical variable information.